General Guidelines. In this sense, contribution of distinct individuals to the outcome of scientific analysis needs to be properly acknowledged.

Similar documents
MedThink SciCom Publication Guidelines

DCVAS Authorship and Publication Policies

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

European Stroke Journal: Declaration Guidelines for Authors

Author Signature: Date: 11 October 2017 The author is signing to confirm the technical content of this document

Journal of Clinical Urology (JCU): Declaration Guidelines for Authors

Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network

MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-P

PROTOCOL HEALTH AND SAFETY CONCERNS FLOWCHART

MARKEY CANCER CENTER STANDARD OPERATING PROCEDURES. SOP No.: MCC Type: Final

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015

Summary of Accomplishments

Trial Committees SOP Number: 47 Version Number: 2.0 Effective Date: 01/02/2017 Review Date: 01/02/2019

Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network

Bayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans

Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network. Approved August 31, 2015

Dr. David D. Lee, Provost and VP for Academic Affairs

Leeds Health Commissioning and System Integration Board. Terms of Reference

Patient Handbook on Stem Cell Therapies

These Board Rules were adopted by the Supervisory Board on 27 September 2016.

ATLAS Authorship Policy

Tip Sheet 17: Review of Research by the Expedited Procedure

Danish Act on Clinical Trials of Medicinal Products 1

Committee on Payments and Market Infrastructures. Charter

NEVRO CORP. CORPORATE GOVERNANCE GUIDELINES. (Adopted October 9, 2014)

Effective Date: October 8, 2015 Policy Number: MHC_RP0301. Corporate Director, HRPP Institutional Official, HRPP

RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust

Authorship and Algorithms: Assessing Authorship at Lilly. Jeffrey W. Clemens, Ph.D. Eli Lilly and Company

CODE OF PRACTICE FOR RESEARCH

ARATANA THERAPEUTICS, INC. CORPORATE GOVERNANCE GUIDELINES

UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration

CODEXIS, INC. CORPORATE GOVERNANCE GUID ELIN ES

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)

The Ethics of Authorship

Authorship and Acknowledgement Guidelines

07/30/2013. Record of Revisions IRB Page 1 of 17

University of Louisiana System

1.0 Scope. 2.0 Abbreviations

Investigator Manual. Human Subjects Protection Program

Louisiana State University System

LOUISIANA COMMUNITY & TECHNICAL COLLEGE SYSTEM Policy No

LOUISIANA COMMUNITY & TECHNICAL COLLEGE SYSTEM Policy No

Information for clinical researchers on transparency of clinical trial reporting

MRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council

Procedure and practical arrangements for the appointment of the Executive Director 45 th Meeting of the Management Board March 2017

Current SCID Gene Transfer Experience

Volunteering for Clinical Trials

Kathy O Kane Kreutzer, M.Ed., Office of Faculty Affairs, School of Medicine March, 2017

Human Research Participant Protection Program Institutional Review Board (IRB)

UT SOUTHWESTERN MEDICAL CENTER AT DALLAS INSTITUTIONAL REVIEW BOARD. Emergency Use of an Investigational Drug, Biologic or Device

EVOKE PHARMA, INC. CORPORATE GOVERNANCE GUIDELINES

Tool for the Self-Assessment of the Institutional Biosafety Committee and Program of Oversight of Recombinant DNA Research

MAXAR TECHNOLOGIES INC. CORPORATE GOVERNANCE GUIDELINES

Editor Guidelines. Ethics Approval and Informed Consent Statements

The role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)

RESEARCH SUPPORT SERVICES FRAMEWORK. Streamlining the management and governance of R&D studies in the NHS

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST

NIAID, DMID Safety Oversight Guidelines

Process for Solicitation and Review of Clinical Trials for NETT

1. Introduction Scope

Acceleron Pharma Inc. Corporate Governance Guidelines

DEMOCRATIC SERVICES COMMITTEE PROPOSAL

3. Human Biomedical Research. Defining Human Biomedical Research

End of Study Notification, Close-Out and Reporting Sponsored Research. Noclor/Spon/S11/01. SOP Reference ID:

Enhanced CET Scheme. Principles and Requirements v2.1. Enhanced CET Scheme Principles and Requirements final version 2.1, December 2012.

Correlative Science and Tissue Banking Procedures. Canadian Cancer Trials Group

MANDATE OF THE BOARD OF DIRECTORS

February 15, Re: Docket No. FDA-2017-D-6159: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

ClinicalTrials.gov REGISTRATION REQUIREMENTS

MSA SAFETY INCORPORATED. Corporate Governance Guidelines. May 15, 2018

ANGLOGOLD ASHANTI LIMITED Registration No. 1944/017354/06 ( AGA or the Company ) SOCIAL, ETHICS AND SUSTAINABILITY COMMITTEE TERMS OF REFERENCE

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009

SWOG Subject: Requests for Patient Data Original Release Date: April 2006 Departments Affected: All Revision Date: May 2013

11.0 FDA-Regulated Research

Developing a European First-in-Human Study: Three Key Decisions

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017

Human Research Protection Program. Plan

HUMAN RESEARCH PROTECTION PROGRAM PLAN

Publication planning and guidelines

Clinical Research: A Multifaceted Discipline

Proposal Writing. J. Daniel Stanley, MD Dept. of Surgery September 11, 2009

Five-step Authorship Framework to Improve Transparency in Disclosing Contributors to Industry-Sponsored Publications. LaVerne Mooney, DrPH

Sample Position Description Board of Directors

TITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19

Version Number: 004. On: June 2018 Review Date: June 2021 Distribution: Essential Reading for: Information for: Page 1 of 10

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Human Research Protection Program Policy

Corporate Governance Policy

CANADIAN SOLAR INC. Corporate Governance Guidelines

TERMS OF REFERENCE FOR THE BOARD OF DIRECTORS I. INTRODUCTION

Embryonic Stem Cell Research Oversight (ESCRO) Committee. Policies and Procedures

If a complaint is filed over a dispute, an investigation may be conducted with the journal editor and author's institution to reach a resolution.

Standard Operating Procedure: Obtaining Informed Consent from Competent Adults for Research Studies. SOP Number: SOP-QA-9 Version No: 1

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

Manuscript Submission Guidelines: Health Services Research and Managerial Epidemiology

ELEMENTS OF A DATA MONITORING PLAN

CfBT Schools Trust Trade Union Recognition and Procedural Agreement

CADTH COMMON DRUG REVIEW. Procedure for the CADTH Common Drug Review

Transcription:

PUBLICATIONS GUIDELINES FOR RETROSPECTIVE STUDIES, NON-INTERVENTIONAL PROSPECTIVE TRIALS, AND PROSPECTIVE CLINICAL TRIALS OF THE EUROPEAN GROUP FOR BLOOD AND BONE MARROW TRANSPLANTATION. VERSION JUNE/2012 Publications in peer-reviewed journals represent one of the most important indicators of the scientific contribution of the European Society or Blood and Marrow Transplantation (EBMT) to the field of stem cell transplantation and cell therapy. Thus, authorship on scientific manuscripts is an important recognition of contributions of individuals for the benefit of EBMT prospective clinical trials or retrospective studies. In this sense, contribution of distinct individuals to the outcome of scientific analysis needs to be properly acknowledged. General Guidelines Authorship on scientific manuscripts is an important recognition of contributions of individuals for the benefit of EBMT prospective or retrospective studies. Some journals have guidelines limiting the number of authors allowed on a publication. Such rules dichotomy can eventually create some conflict of interest. In general, manuscripts should aim to incorporate as many authors as possible as long as they have significantly contributed to the manuscript/ study according to international rules.

Principles for authorship regarding a specific study should be discussed and decided beforehand and clearly documented in the study protocol or study specific publication plan. The Ethical Considerations in the Conduct and Reporting of Research: Authorship and Contributorship (http://www.icmje.org/ethical_1author.html) has to be considered as the basis of the EBMT Publication Guidelines. Any doubt / conflict should in principle be resolved on the basis of the above mentioned international rules. For joint studies with partner organizations (for instance, CIBMTR), authorship should fairly reflect the individual contributions of the participating organizations and should be discussed and agreed on beforehand A «writing» committee (or its equivalent) should usually be appointed for the preparation of an EBMT study manuscript All authors should have had the opportunity to review an advanced version of the manuscript prior to submission All investigators in prospective studies as well as all contributors to retrospective studies should be listed in an appendix to the manuscript in an order that reflects the number of patients included in the study. In case there are several centers with the same number of patients appearing in the Appendix, they will be listed in alphabetical order Manuscripts published on behalf of the EBMT must have in the title: on behalf of the EBMT / on behalf of the xx Working Party of the EBMT. If the title seems too long or is not accepted to a specific journal rules, this statement can be included after the name of the last author. This will ensure a proper scientific visibility of the EBMT. In all cases, the best efforts should be made to highlight the role of the EBMT. Guidelines for Publication of Retrospective Analyses

Retrospective analyses represent > 90% of the scientific output of EBMT. The careful design of the study as well as involvement of relevant people at early stages of its development will ensure the final success of the publication. Writing Committee The writing committee should be invited before start of the study and should be composed by: Investigator developing the scientific idea, principal investigator (PI) WP chairperson Study coordinator / Study statistician Subcommittee chair(s), if appropriate Additional members of the WP, if significant contributions made that qualify for authorship Representatives of centres that potentially will contribute the largest patient numbers to the study according to the pre-study feasibility check will be invited to join the Writing committee before the start of the study Representatives from countries / Study groups that have many potential contributors to the study, who could promote the study within the National / Study Group community ( National Coordinator ) Authorship Position in the Manuscript and Specific Considerations First author. PI of the manuscript. Eventually two authors could share the first position. This situation should also be discussed and agreed on beforehand Last position. Present WP Chair unless the WP chair grants senior authorship to somebody else (e.g. subcommittee chair). If this is the case, the WP Chair could be in the one before the last position If the study was initiated under the supervision of a prior WP chair, the decision of the last position will depend on how developed was the study at the time of change of WP chairpersonship. In any case, this situation should be agreed between the leaving and entering Chairs. Points to consider:

Level of development of the study at the time of WP chair change If data collection finished and manuscript in the phase of statistical analysis / writing, last author could be the prior WP Chair. In that case, the entering WP Chair should be one of the co-authors. If still a significant amount of WP study coordinator / staff time is needed for finalization of the study, last author should be the entering WP chair. If the study is a Joint study (e.g., CIBMTR), last position should be discussed between different groups. Position for Statistician and Study Coordinator, to be discussed during the development of the study and will depend on the amount of work done. In principle, and unless otherwise specified neither of them need to be occupying the second / third position in the authorship list of the manuscript. Representatives of the participating centers. Specific considerations: This representation should be as wide as possible, always taking into consideration the specific guidelines / requests of the journal and the number of patients included in the analysis Position of representative of the centers will depend on the number of patients included in the study Centers not being able to appear in the list of co-authors due to low number of patients included will appear appropriately mentioned in the Appendix. Author obligations Given the fact that the EBMT has a scientific and economical interest in a timely and successful publication of retrospective studies performed with EBMT data and resources, PIs / first authors granted with these resources for conducting an EBMT retrospective study should aim at timely preparation of a manuscript draft once the study is closed and the statistical analysis is done. If the PI fails to deliver a manuscript within a reasonable time frame (usually 3 months after having received the results of the statistical analysis), the WP chair may transfer

manuscript writing responsibility / first authorship to another investigator or take it over by herself/ himself. Independent Review Board Approval Some journals are requesting an Independent Review Approval (IRB) of the study before the publication of the manuscript. The scientific meeting of the relevant WP / WPs minutes that indicates the discussion of the proposal, potential modifications and final approval of the protocol could be used for this purpose. WP chairs ensure that all studies are performed in accordance with the principles of the declaration of Helsinki. Guidelines for Publication of Non-Interventional Prospective Analyses and Prospective Clinical Trials Presentation of data coming from non-interventional prospective trials and prospective clinical trials also represent a source of scientific output for the EBMT. Publication Plans should be developed at the earliest stages of trial planning and should follow the same general rules / reference manuscripts as what has been previously described for Retrospective Analyses Authorship criteria should be discussed at the start of the study and should reflect the individual contributions to the trial Rules for being invited to participate in the Writing Committee The investigator coordinating the writing of the manuscript Study coordinator Study statistician National PIs Other potential collaborators who have significantly contributed to conception, design, analysis or interpretation of the data

Investigators who have provided a substantial proportion of the study population for the study WP Chair. Chair of a subcommittee, if applicable A representative of the pharma company sponsoring the study, if applicable, if he/she fulfils ICJME criteria for authorship Authorship Position in the Manuscript and Specific Considerations Same strategy than Retrospective Studies Other Types of Scientific Output on Behalf of the EBMT Invited Reviews, Educational Manuscripts (in general non-peer reviewed manuscripts), Consensus and Guideline Papers Active member so the EBMT can be invited to participate in other type of manuscripts, not necessarily perr-reviewed : invited reviews, educational manuscripts, guidelines, consensus papers. The name of the EBMT should adequately be acknowledged, always reflecting the scientific input that EBMT has provided to the manuscript: o Consensus and Guideline Papers. Publication rules should follow the same pathway than Retrospective Analysis o Educational Manuscripts, Invited Reviews. This refers to the case that a relevant WP member has been invited to write one of these types of manuscripts. If this is the case and the manuscript is to have the EBMT Logo it should contain if possible information coming from the relevant EBMT WP scientific activity and have been reviewed by the Chair of the WP before submission.